4. Taltz

Eli Lilly

Active ingredient: ixekizumab
Disease: psoriasis
Peak sales estimate: $1 billion-plus
Approved: March 22
Company: Eli Lilly

The scoop: Big Pharma’s pipelines are nearly bursting with next-gen psoriasis prospects, but Lilly managed to beat most of its peers to market with Taltz. While it couldn’t touch Novartis’ Cosentyxwhich had picked up two additional indications, in ankylosing spondylitis and psoriatic arthritis by the time Taltz came aroundit’s still making good launch headway with its own contender. On its Q3 earnings call, the Indianapolis drugmaker said its newcomer was snagging more than 10% of new-to-brand share, on par with its Novartis nemesis and ahead of anti-TNF giant Enbrel from Amgen. -- Carly Helfand

4. Taltz
Read more on

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.